China's SAMR weighs generic-drug entry as potential competition in merger reviews
By MLex Staff ( September 7, 2026, 07:48 GMT | Insight) -- Expected entry of generic drugs following the expiry of patent exclusivity may provide an effective competitive constraint in Chinese merger reviews, according to analysis of three cases published by China’s State Administration for Market Regulation. The cases also shed light on eligibility for simplified reviews and the use of industry-specific metrics to calculate market shares.Expected entry of generic drugs following the expiry of patent exclusivity may provide an effective competitive constraint in Chinese merger reviews, according to analysis of new cases published by the country’s antitrust regulator....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.